Incorporation of pharmacokinetic and pharmacodynamic data into risk assessments. - Wikidata - awgldk - TriplyDB

Incorporation of pharmacokinetic and pharmacodynamic data into risk assessments.

Incorporation of pharmacokinetic and pharmacodynamic data into risk assessments.

http://www.wikidata.org/entity/Q33519666

about

Advances in inhalation dosimetry models and methods for occupational risk assessment and exposure limit derivation Applying mode-of-action and pharmacokinetic considerations in contemporary cancer risk assessments: an example with trichloroethylene.Systems Biology to Support Nanomaterial Grouping.Incorporating population variability and susceptible subpopulations into dosimetry for high-throughput toxicity testing.Evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry.Organ growth functions in maturing male Sprague-Dawley rats based on a collective database.Organ growth functions in maturing male Sprague-Dawley rats.

P2860

Q23912442-D0904927-92FB-4F16-9A66-87F9A64609E7 Q35961038-344EC4A6-E168-4B60-AB8A-63519C87F88B Q38974885-7F86500A-CA04-4653-8925-058DA8000FD2 Q42001999-23BED72C-2096-4808-985E-AC8AEDC94224 Q44824434-5A30BB3A-CDBE-4EFE-8C16-9FD1970338CC Q48170625-742ABE57-672C-4EE5-B5A5-04356B42DA6A Q48190885-88C58881-3D9D-4EBE-94C7-052B21203B7D

P2860

Incorporation of pharmacokinetic and pharmacodynamic data into risk assessments.

http://www.wikidata.org/entity/Q33519666

description

2004 nî lūn-bûn

@nan

2004 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Incorporation of pharmacokinetic and pharmacodynamic data into risk assessments.

@ast

Incorporation of pharmacokinetic and pharmacodynamic data into risk assessments.

@en

Incorporation of pharmacokinetic and pharmacodynamic data into risk assessments.

@nl

type

label

Incorporation of pharmacokinetic and pharmacodynamic data into risk assessments.

@ast

Incorporation of pharmacokinetic and pharmacodynamic data into risk assessments.

@en

Incorporation of pharmacokinetic and pharmacodynamic data into risk assessments.

@nl

prefLabel

Incorporation of pharmacokinetic and pharmacodynamic data into risk assessments.

@ast

Incorporation of pharmacokinetic and pharmacodynamic data into risk assessments.

@en

Incorporation of pharmacokinetic and pharmacodynamic data into risk assessments.

@nl

P1433

Q33519666-6322C5DA-13C3-4BFA-804D-CE926EA99814

P1476

Q33519666-C0A65EFA-6264-43BF-9AC7-3A4CE0158863

P2093

Q33519666-12B9DC2C-713E-492B-B88C-8993C9AAF198

Q33519666-2EA22BB0-EA69-4AB5-9FE0-7CA07E9A8D1A

Q33519666-5593E046-20AD-49D7-99F7-829B87580A91

Q33519666-DB6DC6E3-9404-4FC3-A3BD-9CD91AB54B6F

Q33519666-DE7FFC8B-64A7-4436-A3FA-0F14C9AE9435

P2860

Q33519666-00CA13D6-E371-4127-BDAF-CE75635FF3BD

Q33519666-18E89334-5E31-42E7-82A9-94EA6668F75A

Q33519666-1B90A3A0-89FA-4657-9046-05FC47E8AC7B

Q33519666-219AACB2-D434-40C0-AAF1-50DB89873235

Q33519666-21C320DF-56B1-4BA8-9068-162EAF603095

Q33519666-25A39430-9078-4299-B568-C93B4B86AA23

Q33519666-3E4DA569-70A3-4F3F-97B6-0C115CD31F42

Q33519666-43FD88ED-CE5D-4FEF-8D38-1EBAD421BBDF

Q33519666-55DD566B-566D-447C-B641-2ABBDDABE0D6

Q33519666-701425F5-BE40-46EC-B582-D924BDCFE07B

P304

Q33519666-D732A606-2ED3-4907-8DB1-53DCE5139F17

P31

Q33519666-4A9B2828-A162-4216-87DE-C82804A35AF1

P356

Q33519666-D40FE56F-3992-484E-BA48-71BDB0E854E6

P433

Q33519666-30173E93-6409-4EF9-B8A5-F950DE7A484E

P478

Q33519666-6CB5AACC-5763-4900-BF89-DFAA09AB556A

P50

Q33519666-729E5EA2-3D18-4DCB-9CB7-2AF54B514DDB

P577

Q33519666-EF8509AF-4D18-4DDE-9175-735CC3DE026A

P5875

Q33519666-9D30BBE3-643B-400C-A8BA-B13D0E998184

P698

Q33519666-492B27C8-94C0-4A89-925F-47E8BE0BB6C1

P356

15376520490429382

P1433

Toxicology Mechanisms and Methods

P1476

Incorporation of pharmacokinetic and pharmacodynamic data into risk assessments.

@en

P2093

Gregory L Kedderis

http://www.w3.org/2001/XMLSchema#string

Harvey Clewell

http://www.w3.org/2001/XMLSchema#string

John C Lipscomb

http://www.w3.org/2001/XMLSchema#string

Kannan Krishnan

http://www.w3.org/2001/XMLSchema#string

M E Bette Meek

http://www.w3.org/2001/XMLSchema#string

P2860

Cytochrome P450-dependent metabolism of trichloroethylene: interindividual differences in humans

Variance of microsomal protein and cytochrome P450 2E1 and 3A forms in adult human liver

Interindividual variance of cytochrome P450 forms in human hepatic microsomes: correlation of individual forms with xenobiotic metabolism and implications in risk assessment

Pharmacokinetics of toxic chemicals in breast milk: use of PBPK models to predict infant exposure

Extrapolation of in vitro enzyme induction data to humans in vivo.

An approach for the quantitative consideration of genetic polymorphism data in chemical risk assessment: examples with warfarin and parathion.

Genetic polymorphisms in assessing interindividual variability in delivered dose.

Review and evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry.

Physiologically based pharmacokinetic model for the inhibition of acetylcholinesterase by organophosphate esters.

Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance.

P304

145-158

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/15376520490429382

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

P577

2004-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40728641

http://www.w3.org/2001/XMLSchema#string

P698

20021141

http://www.w3.org/2001/XMLSchema#string